Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Home Access HIV test use reveals three-times positive rate compared to national average.

This article was originally published in The Tan Sheet

Executive Summary

HOME ACCESS HIV TEST RESULTS SHOW .9% SEROPOSITIVE RATE -- three times the estimated national rate -- among 152,044 users of the over-the-counter HIV home blood test service. In its Dec. 2 "HIV Counseling & Testing Report," Hoffman Estates, Ill.-based Home Access announces data collected anonymously during pretest counseling from August 1996 through September 1997. The .9% seropositive rate is higher than the Centers for Disease Control & Prevention's recently estimated rate of .3%. The Home Access survey is intended to complement CDC's annual efforts to provide a demographic summary of HIV cases for those tested at publicly-funded sites, the company said. The seropositive rate at publicly funded sites for 1995 was 1.2%, according to CDC's report. Home Access markets the only HIV test service available OTC.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087848

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel